Orlistat (also known as tetrahydrolipstatin) is a drug designed to treat obesity. It is marketed as a prescription drug under the trade name Xenical by Roche in most countries, and is sold over-the-counter as Alli by GlaxoSmithKline in the United Kingdom and the United States. Its primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet. Orlistat is the saturated derivative of lipstatin, a potent natural inhibitor of pancreatic lipases isolated from the bacterium Streptomyces toxytricini. However, due to its relative simplicity and stability, orlistat was chosen over lipstatin for development as an anti-obesity drug. The effectiveness of orlistat in promoting weight loss is definite, though modest. Pooled data from clinical trials suggest that people given orlistat in addition to lifestyle modifications, such as diet and exercise, lose about 2–3 kilograms (4.4–6.6 lb) more than those not taking the drug over the course of a year. Orlistat also modestly reduces blood pressure, and appears to prevent the onset of type 2 diabetes, whether due to weight loss itself or to other effects; in a large randomized controlled trial, orlistat was found to reduce the incidence of diabetes by nearly 40% in obese people. Orlistat is notorious for its gastrointestinal side effects (sometimes referred to as treatment effects), which can include steatorrhea (oily, loose stools). These decrease with time, however, and are the most frequently reported adverse effects of the drug. In the United States and the European Union, orlistat is available for sale without a prescription. Over-the-counter approval was controversial in the United States, with consumer advocacy group Public Citizen repeatedly opposing it on safety and efficacy grounds. Generic formulations of orlistat are available in some countries. In Australia it is listed as an S3 medication, which means it's available over the counter in pharmacies. At times, such as in spring 2012, orlistat has come into short supply, with consequent price increases because of nonavailability of one of the drug's components. Product name: Orlistat CAS NO.: 96829-58-2 MF: C29H53NO5 MW.: 495.7348 Application: lose weight DeliveryTime: one week Package: 25KG/Drum or as per your requirement Port: Guangzhou Production Capacity: 1000 Kilogram/Week Storage: store in cool, dry, ventilated place Transportation: by air;by sea; by express；Normal Good MOQ: 1 Kilogram Appearance---White to off white powder Identification---Similar to the standard Melting Point---68-73℃ Loss On Drying---≤0.5% Heavy metal---≤10ppm Assay (On dried basis)---≥98%---99.12% Residue on ignition---≤0.1% Each impurity---≤0.2% Conclusion: This product conforms to the enterprise standard detection.
lose weight

CAS NO:96829-58-2

EC NO:

Molecular Formula:C₂₉H₅₃NO₅

Molecular Weight:495.7348

Synonyms:;(S)-2-FORMYLAMINO-4-METHYL-PENTANOIC ACID (S)-1-[[(2S,3S)-3-HEXYL-4-OXO-2-OXETANYL]METHYL]-DODECYL ESTER;RO-18-0647;N-FORMYL-L-LEUCINE (1S)-1-[[(2S,3S)-3-HEXYL-4-OXO-2-OXETANYL]METHYL]DODECYL ESTER;XENICAL;(-)-Tetrahydrolipstatin;Orlipastat;(1S)-1-{[(2R,3S)-3-hexyl-4-oxooxetan-2-yl]methyl}dodecyl N-formyl-D-leucinate;[(1S)-1-[[(2S)-3-hexyl-4-oxo-oxetan-2-yl]methyl]dodecyl] (2S)-2-formamido-4-methyl-pentanoate;

Molecular Structure:

CAS NO:96829-58-2

EC NO:

Molecular Formula:C₂₉H₅₃NO₅

Molecular Weight:495.7348

Synonyms:;(S)-2-FORMYLAMINO-4-METHYL-PENTANOIC ACID (S)-1-[[(2S,3S)-3-HEXYL-4-OXO-2-OXETANYL]METHYL]-DODECYL ESTER;RO-18-0647;N-FORMYL-L-LEUCINE (1S)-1-[[(2S,3S)-3-HEXYL-4-OXO-2-OXETANYL]METHYL]DODECYL ESTER;XENICAL;(-)-Tetrahydrolipstatin;Orlipastat;(1S)-1-{[(2R,3S)-3-hexyl-4-oxooxetan-2-yl]methyl}dodecyl N-formyl-D-leucinate;[(1S)-1-[[(2S)-3-hexyl-4-oxo-oxetan-2-yl]methyl]dodecyl] (2S)-2-formamido-4-methyl-pentanoate;

Molecular Structure: